Next Article in Journal
Opipramol Inhibits Lipolysis in Human Adipocytes without Altering Glucose Uptake and Differently from Antipsychotic and Antidepressant Drugs with Adverse Effects on Body Weight Control
Next Article in Special Issue
Is There a Role for the Therapeutic Drug Monitoring of Colistin? An Overview
Previous Article in Journal
(Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer
Previous Article in Special Issue
[68Ga]Ga-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging
Open AccessReview

2019 FDA TIDES (Peptides and Oligonucleotides) Harvest

1
KRISP, School of Laboratory of Medicine and Medical Science, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa
2
School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa
3
CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine and Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Pharmaceuticals 2020, 13(3), 40; https://doi.org/10.3390/ph13030040
Received: 11 February 2020 / Revised: 2 March 2020 / Accepted: 3 March 2020 / Published: 5 March 2020
(This article belongs to the Collection The Story of Successful Drugs and Recent FDA-Approved Molecules)
2019 has been an excellent year in terms of peptides and oligonucleotides (TIDES) approved by the FDA. Despite the drop in the number of total drugs approved by the FDA in 2019 in comparison with 2018 (48 vs. 59), the total number of TIDES authorized increased (seven vs. three). Year after year, TIDES are increasingly present in therapy, as imaging agents, theragnostic and constituent moieties of other complex drugs, such as antibody drug conjugates. This means a consolidation of these kinds of drugs in the pharmaceutical arena, paving the way in the coming years for the approval of others for diverse medical indications. Here the TIDES approved in 2019 are analyzed in terms of chemical structure, medical target, mode of action, and adverse effects. View Full-Text
Keywords: afamelanotide; bremelanotide; DOTATOC; drugs; 68Ga-DOTATOC; enfortumab vedotin; golodirsen; givosiran; polatuzumab vedotin; oligonucleotides; peptides; pharmaceutical market afamelanotide; bremelanotide; DOTATOC; drugs; 68Ga-DOTATOC; enfortumab vedotin; golodirsen; givosiran; polatuzumab vedotin; oligonucleotides; peptides; pharmaceutical market
Show Figures

Figure 1

MDPI and ACS Style

Al Shaer, D.; Al Musaimi, O.; Albericio, F.; de la Torre, B.G. 2019 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals 2020, 13, 40.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop